


## Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors Suppresses Defective Hippo Signaling

Wenchao Lu,<sup>a</sup> Mengyang Fan,<sup>b</sup> and Tinghu Zhang<sup>c</sup>, Nathanael S. Gray<sup>c,\*</sup>

<sup>a</sup> Lingang Laboratory, Shanghai 200031, China; <sup>b</sup> Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; <sup>c</sup> Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States.

E-mail: luwenchao@lglab.ac.cn

The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription by YAP has been implicated in a number of malignancies, and this complex represents a promising target for drug discovery. However, both YAP and its extensive binding interfaces to TEAD have been difficult to address using small molecules, mainly due to a lack of druggable pockets<sup>1</sup>. Recently, TEADs were recognized as being palmitoylated in cells, which provides an opportunity to develop cysteine-directed covalent small molecules for TEAD inhibition<sup>2</sup>. Here, we employed covalent fragment screening approach followed by structure-based design to develop an irreversible TEAD inhibitor MYF-03-176. Using a range of in vitro and cell-based assays we demonstrated that through a covalent binding with TEAD palmitate pocket, MYF-03-176 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity and inhibits cell growth of Hippo signaling defective malignant pleural mesothelioma (MPM) in vitro and in vivo. Further, a cell viability screening with a panel of 903 cancer cell lines indicated a high correlation between TEAD-YAP dependency and the sensitivity to MYF-03-176 in cancer cells including those derived from mesothelioma and liposarcoma.



**Figure 1.** Covalent fragment screen led to the identification of Y-shaped TEAD inhibitors.

### References

1. Pobbati, A. V.; Kumar, R.; Rubin, B. P.; Hong, W., Therapeutic targeting of TEAD transcription factors in cancer. *Trends Biochem Sci* **2023**, *48* (5), 450-462.
2. Chan, P.; Han, X.; Zheng, B.; DeRan, M.; Yu, J.; Jarugumilli, G. K.; Deng, H.; Pan, D.; Luo, X.; Wu, X., Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. *Nat Chem Biol* **2016**, *12* (4), 282-9.